Emergent BioSolutions Inc. (NYSE: EBS) today announced a contract modification has been secured to deliver CNJ-016® [Vaccinia Immune Globulin Intravenous ...

Emergent BioSolutions shares rose after the company disclosed that it will supply additional doses of CNJ-016, a treatment ...

About an hour after the closing bell, shares of Emergent were trading 6.4% higher, at $7.31. The company's shares ended the day's regular session at $6.87, a gain of 3.7%.

Emergent BioSolutions (EBS) has secured a $51.9M contract modification award to deliver CNJ-016 to the Administration for Strategic Preparedness and Response (A ...

Investing.com -- Emergent BioSolutions Inc (NYSE: EBS) stock rose 6.3% after the company announced a contract modification to deliver additional doses of its smallpox vaccination complication ...

South Korea has developed the world's first recombinant protein-based anthrax vaccine, a major step toward self-sufficiency ...

PennantPark Investment Corporation (the 'Company') (NYSE: PNNT) declares its monthly distribution for July 2025 of $0.08 per share, payable on August 1, 2025 to stockholders of record as of July 15, ...

Synedgen, Inc., a biotechnology company with a validated platform targeting human glycobiology to treat a range of diseases ...

The real-world evidence solutions market is largely driven by the increasing prevalence of chronic diseases and their impact on real-world healthcare ...

A little less than a year after topping up its medical countermeasure contracts with Emergent BioSolutions, the federal ...